Multiple myeloma (MM) is an incurable disease and is the second most common haematologic malignancy in the world. Over the past decade, therapies for MM have improved their safety profile and efficacy. However, patients with MM eventually stop responding to treatment and relapses are very common. Isatuximab (Isa), a monoclonal antibody, is approved to treat relapsed/refractory (RR) MM in combination with either pomalidomide (P) and dexamethasone (d) or carfilzomib (K) and d.
Latest articles
All articles
